Analyst Price Targets — AKTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 20, 2026 11:49 am | — | Maxim Group | $30.00 | $11.01 | TheFly | Akari Therapeutics upgraded to Buy from Hold at Maxim |
| December 5, 2022 6:10 am | — | H.C. Wainwright | $1,200.00 | $430.80 | Benzinga | HC Wainwright & Co. Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $1.5 |
Latest News for AKTX
Video webcast now available here
AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027
Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs)…
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $9.24 and traded as low as $7.19. Akari Therapeutics shares last traded at $7.36, with a volume of 24,072 shares traded. Wall Street Analysts Forecast Growth
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AKTX.
U.S. House Trading
No House trades found for AKTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.